NCT07116681View on ClinicalTrials.gov

Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions

Pulmonary Hypertension

Interventions

DRUG

Inhaled treprostinil

Inhaled treprostinil is an inhaled prostacyclin analog which triggers pulmonary arterial dilation. This is the only intervention in this trial.

Sponsors

Collaborators (1)

United Therapeutics

All Listed Sponsors

collaborator

United Therapeutics

INDUSTRY

lead

University of California, San Diego

OTHER